TRIPLE NEGATIVE BREAST NEOPLASMS
Clinical trials for TRIPLE NEGATIVE BREAST NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST NEOPLASMS trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cancer drug trial seeks to tame advanced tumors
Disease control TerminatedThis early-stage study tested a new drug called Felmetatug Vedotin, both alone and combined with pembrolizumab, in people with advanced solid tumors that had spread or could not be removed by surgery. The main goal was to find safe dosage levels and understand side effects for ca…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Early cancer drug trial halted before full testing
Disease control TerminatedThis early-stage study tested a new oral drug called NUV-868, both alone and combined with two existing cancer medications (olaparib or enzalutamide), in adults with advanced solid tumors. The goal was to find safe doses and see if these treatments could help control cancers like…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New pill tested as potential lifeline for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Terminated trial tests new combo for Tough-to-Treat breast cancer
Disease control TerminatedThis study tested whether adding an experimental drug called leronlimab to standard chemotherapy (carboplatin) could help control advanced triple-negative breast cancer that had a specific marker (CCR5+). The first part aimed to find a safe dose, and the second part planned to se…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Terminated trial tests unusual drug duo against tough breast cancers
Disease control TerminatedThis study tested whether combining an immunotherapy drug (pembrolizumab) with mifepristone could help control advanced breast cancers that lack the HER2 marker. It involved 24 patients with either triple-negative or hormone receptor-positive breast cancer that had spread or coul…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC